Purple Squirrel Economics, New York, NY 10010, USA.
Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
J Comp Eff Res. 2018 Aug;7(8):775-784. doi: 10.2217/cer-2018-0034. Epub 2018 May 31.
Eltrombopag and romiplostim are comparable second-line therapies in chronic immune thrombocytopenia. Treatment decisions are made in different contexts. A framework was created to outline decision pathways for physicians and payers. The costs of drugs, administration, routine care, bleeding, other adverse events and mortality were included in the year-long calculation of total costs from a US private payer perspective. Treatment parameters and outcome data were obtained from relevant clinical trials. The total cost per year, per patient of eltrombopag was US$51,000 versus US$76,000 for romiplostim. Drug costs and costs associated with bleeding-related events were the main drivers of cost difference. This framework facilitates decision-making in the management of chronic immune thrombocytopenia with eltrombopag and romiplostim.
依洛尤单抗和罗米司亭在慢性免疫性血小板减少症二线治疗中具有可比性。治疗决策是在不同的背景下做出的。本研究构建了一个框架，以概述医生和支付者的决策路径。从美国私人支付者的角度，在为期一年的总费用计算中，纳入了药物、给药、常规护理、出血、其他不良事件和死亡率相关成本。治疗参数和结局数据来自相关临床试验。依洛尤单抗每年每位患者的总费用为 51000 美元，而罗米司亭为 76000 美元。药物成本和与出血相关事件相关的成本是造成成本差异的主要因素。本框架有助于在依洛尤单抗和罗米司亭治疗慢性免疫性血小板减少症的管理中做出决策。
